Merck, Sanofi delay animal health JV; Dutch gov't to sell off public vaccine ops;

@FiercePharma: J&J cuts Weldon's bonus, but grants raise for 2011. Story | Follow @FiercePharma

> Merck said ongoing reviews by antitrust regulators will delay the formation of a new animal-health joint venture with Sanofi-Aventis until the third quarter. Report

> The Dutch government has put the manufacturing operations of the Netherlands Vaccine Institute up for sale following a decision to cease government-owned production of vaccines. News

> PDL BioPharma has agreed to settle a legal dispute with Novartis; it will pay the Swiss drugmaker an amount based on the net sales of the eye drug Lucentis this year and beyond. Item

> German generics maker Stada forecast sales and earnings to grow this year and next and said cost cuts may help boost 2011 core earnings to a fresh all-time high. Article

> Ranbaxy Laboratories, controlled by Japan's Daiichi Sankyo, will market four of the parent company's drugs in Singapore. Report

> The FDA has suggested manufacturers consider removing zinc from denture creams following reports of neurological problems that might be associated with zinc poisoning. Story

> Shire said its Intuniv hyperactivity drug has been approved by FDA for use in combination with a stimulant to treat children and adolescents aged six to 17. Item

> The U.K.'s National Institute for Health and Clinical Excellence has put out a call to Swiss drugmaker Roche for more data in support of cancer drug MabThera's use on the National Health Service. Article

> The European Medicines Agency's decision to allow former executive director Thomas Lonngren to take up an advisory role within the pharmaceutical industry--just weeks after leaving his position at EMA--risks conflicts of interest, campaigners have claimed. Report

Biotech News

@FierceBiotech:  Aggressive midcap biotechs suit up for the M&A game. Article | Follow @FierceBiotech

@JohnCFierce:  Biotech and pharma boundaries will continue to blur. Follow @JohnCFierce 

> Daiichi Sankyo nabs tiny Plexxikon in $935M deal. Story

> Forest, Nycomed win narrow FDA approval on new COPD drug. Item

> Pfizer updates late-stage pipeline prospects and discards. Article 

Biotech Research News

> The search for model of 'animal model'. Item

> Children often an afterthought in drug development. Report

> Gene therapy forces breast cancer to self-destruct. News

> HP uses inkjet printer tech for drug discovery. Article

> Study: PSA velocity should not determine biopsy. Item

Manufacturing News

> GSK boosts plant job cuts by 20. Article

> FDA, Triad stung in alcohol pad recall. News

> Constantino defies Cramer on pharma stocks: Buy. Report

> Report: 50% of pharma serializing in 2011. Story

> Pharma lobbies for tougher theft penalties. News 

> Cialis fakes maker sentenced in London. Item

And Finally... President Obama signed on to a bipartisan plan that would let states opt out of federal requirements three years earlier than slated in the original healthcare reform law. Report

Suggested Articles

BMS’s Opdivo has plenty of competition in its current bladder cancer indication—so it’s hoping to strike out on its own in a new area of the disease.

The Japanese approval, under the brand name Jyseleca, came a month after an FDA complete response letter that asked Gilead for more data.

The Trump Administration has opened the doors for Florida and other states to import prescription drugs from Canada—despite industry objections.